Rising Biotech Stock Surpasses Expectations So Far in 2025
Precigen, Inc. (NASDAQ:PGEN) has seen a significant surge in value this year following the FDA's Priority Review of its investigational AdenoVerse gene therapy, PRGN-2012, for treating adults with recurrent respiratory papillomatosis (RRP). The company's stock price has increased by 55.36% so far in 2025, ranking it 9th on our list of biotech stocks that are skyrocketing this year. With a consensus price target of $7 implying 300% upside, Precigen, Inc. is gaining attention from investors.
- The growing demand for gene and cell therapies highlights the potential for companies like Precigen, Inc. to address unmet medical needs in therapeutic areas such as immuno-oncology and autoimmune disorders.
- As the biotech industry continues to evolve with advancements in AI technology, how will innovative treatments and precision medicine impact the landscape of rare diseases and increasing healthcare spending globally?